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Abstract
Background: Iris metastasis in patients with gastric cancer is extremely rare. Herein, it is aimed to report on a
patient with gastric adenocarcinoma and iris metastasis.
Case presentation: A 65-year-old patient with the history of gastric cancer was admitted for eye pain and eye
redness on his left eye. There was ciliary injection, severe +4 cells with hypopyon in the anterior chamber and a
solitary, friable, yellow-white, fleshy-creamy vascularized 2 mm × 4 mm mass on the upper nasal part of the iris
within the left eye. The presented patient’s mass lesion in the iris fulfilled the criteria of the metastatic iris lesion’s
appearance. The ocular metastasis occurred during chemotherapy.
Conclusions: Iris metastasis can masquerade as iridocyclitis with pseudohypopyon or glaucoma. In patients with a
history of gastric cancer that present with an iris mass, uveitis, and high intraocular pressure, ocular metastasis of
gastric cancer should be a consideration.
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Background
Metastasis from systemic carcinoma to the eye was re-
ported to occur in 4 % [1] and 8 % [2] of cases in two
autopsy-based studies. The choroid is the most frequent
site of ocular metastasis of systemic cancer. The meta-
static spread to the iris was uncommon and quite rare [3].
Gastric adenocarcinoma is among the most common
causes of cancer-related mortality worldwide [4]. Gastric
adenocarcinoma usually develops slowly, but eventually
progresses to multiple sites of metastasis [5]. Choroidal
metastatic tumors of gastric cancer origin—though rar-
e—have been reported [5–7]. A recent study that included
160 metastatic tumors of systemic cancer origin in the iris
in 107 eyes of 104 patients reported no cases of metastasis
in the iris of gastric cancer origin [8].The iris is an ex-
tremely rare site of gastric cancer metastasis. To the best
of our knowledge, the English-language literature includes
just one such case, which was reported by Imamura et al.
[9]. In that case, metastasis in the iris occurred 3 years
after gastric cancer was diagnosed. Herein, we report on
the second case of gastric adenocarcinoma metastasizing
to the iris; metastasis occurred 8 months after the cancer
was diagnosed and while the patient was receiving sys-
temic chemotherapy.
Case presentation
A 65-year-old male presented in April 2015 with a chief
complaint of redness and pain in the left eye within the
last 2 weeks. Past medical history included highly
dysplastic undifferentiated gastric adenocarcinoma that
was diagnosed by gastric biopsy via esophagogastroduo-
denoscopy in August 2014. The patient had undergone
18F-fluorodeoxyglucose-positron emission tomography/
computed tomography (18F-FDG-PET/CT), which showed
multiple uptakes in the distal stomach at the antrum and
pylorus, lesser curvature, peripancreatic lymph nodes, and
at multiple sites in the liver, but no uptake by the globe or
periocular region. An additional biopsy specimen was ob-
tained from a mass in the liver in September 2014, which
showed metastasis of gastric adenocarcinoma. To differen-
tiate between primary and a metastatic liver mass lesion,
immunohistochemistry was performed. The liver lesion
from gastrointestinal system was considered metastatic
with the strong cytokeratin positivity, strong CDX2 focal
positivity, focal cytokeratin 20 positivity, and strong cyto-
keratin 7 positivity. Both the primary lesion from the gas-
tric biopsy and the metastatic liver lesion shared the same
high-grade dysplastic gland formation under microscopy.
The patient’s final diagnosis was stage 4 gastric cancer with
multiple metastases.
Chemotherapy was initiated in September 2014 with
docetaxel, cisplatin, leucovorin, and 5-FU (modified DCF
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protocol). The modified DCF protocol was applied as fol-
lows: (1) 40 mg/m2 in total 75 mg docetaxel with 500 cc
5 % dextrose in 1 h intravenous infusion on the first day,
(2) 40 mg/m2 in total 75 mg cisplatin with 500 cc isotonic
saline in 1 h intravenous infusion, (3) 400 mg/m2 in total
770 mg leucovorin in 500 cc 5 % dextrose in 1 h intraven-
ous infusion, and (4) 400 mg/m2 in total 770 mg 5-FU
intravenous bolus injection. On the first day following
intravenous bolus injection, 5-FU was administered
2000 mg/m2 in total 3860 mg with infusion pump con-
tinuously during the first and second day. This treatment
scheme was repeated 2 weeks apart. Follow-up 18F-FDG-
PET/CT in January 2015 showed stable gastric lesions and
no uptake within the globe itself. The patient’s visual com-
plaints started in April 2015. Visual acuity was 20/20 in
the right eye (oculus dexter (OD)) and 20/50 in the left
eye (oculus sinister (OS)). Intraocular pressure was
16 mmHg OD and 32 mmHg OS. There was ciliary injec-
tion, minimal upper nasally located corneal edema, severe
+4 cells with hypopyon in the anterior chamber and a soli-
tary, friable, yellow-white, fleshy-creamy vascularized
2 mm× 4 mm mass on the upper nasal part of the iris
within OS (Fig. 1). During gonioscopy examination, the
mass obscured the angle structures in the upper nasal por-
tion of the iris. In addition, there was a 0.5 mm× 0.5 mm
yellow-white creamy mass in the 7 o’clock position on the
mid-peripheral iris (Fig. 1). Fundus examination was nor-
mal OS. The right eye was pseudophakic, and the ophthal-
mic examination was otherwise unremarkable.
Two days after identifying the possible iris metastasis, or-
bital MRI was performed to define the posterior extension
of the mass before the needle aspiration biopsy; the mass
was shown to be limited to the iris; no other mass lesions
were noted at the ciliary body, choroid, optic nerve, extrao-
cular muscles, or intra-orbital fat. Fine-needle aspiration
biopsy was scheduled 1 day after the report of orbital MRI
was obtained, but the patient passed away after a sudden
respiratory arrest, nearly 10 months after the primary
tumor was diagnosed.
Discussion
Between 90 and 95 % cases of ocular metastasis from sys-
temic cancer occur in the choroid [3]. A survey of 950
metastatic foci in 520 eyes with uvea metastasis showed
involvement of the choroid in 88 % and iris in 9 % of the
eyes [3]. It was posited that uvea metastasis occurs in the
choroid more commonly than in the iris because of the
rich blood supply to the posterior choroid via the poster-
ior ciliary arteries. This facilitates a greater volume of
blood flow and is associated with a greater risk of meta-
static emboli, as compared to the anterior ciliary vessels
that supply blood to the iris [10].
Gastric adenocarcinoma metastasizes to numerous
sites; the most common sites are the liver and non-
regional or distant lymph nodes, whereas choroidal and
iris metastases are very rare [5]. To the best of our
knowledge in the English-language literature, only one
similar case of isolated iris metastasis of gastric cancer
has been reported [9], and the presented case is the
second. In the earlier case, the iris mass was white and
lacework-like and encompassed the entire area of the
iris. In contrast, the iris mass was solitary, friable,
yellow-white, and fleshy and presented with a pro-
nounced ciliary injection, in the current case.
A recent study about iris metastasis of systemic cancer
among 104 patients reported that only three patients
had iris metastasis of esophageal cancer, and only two
patients had iris metastasis of colon cancer; no patient
had iris metastasis of gastric cancer [8]. One case report
describes a patient with iris metastasis from esophagus
as the primary site of the gastrointestinal tract system
[11]. In that case, iris metastasis was controlled using
systemic chemotherapy. Unfortunately, the iris metasta-
sis in the present case was diagnosed while the patient
was undergoing systemic chemotherapy. Shields et al.
[3] studied 950 uvea metastases in 520 eyes and re-
ported that gastrointestinal tract carcinoma was the pri-
mary site in 4 % of the uvea metastatic tumors. Soysal et al.
[12] reported one uvea metastasis from the gastrointes-
tinal tract in a survey of 38 eyes, in which the choroid was
the only site of metastasis of gastrointestinal carcinoma.
Gastric carcinomas generally prefer metastasizing to the
choroid [6]; however, multiple cases of gastric adenocar-
cinoma metastases to the eyelid and conjunctiva [13] and
optic nerve [14] have been reported versus just one case
report of isolated iris metastasis of gastric cancer [9].
Iris metastasis can manifest with a stromal nodule, ill-
defined iris thickening, pain, iridocyclitis, or hyphema. In
1995, Shields et al. [8] published a clinically based analysis
Fig. 1 The patient’s left eye. Solitary, friable, yellow-white, fleshy,
creamy vascularized 2 mm× 4 mm mass on the nasal upper part of
the iris and a small 0.5 mm× 0.5 mm yellow-white creamy mass at
the 7 o’clock position on the mid-peripheral iris
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of 40 cases of iris metastasis during a 20-year period,
reporting that the patients’ primary complaints were
blurred vision, ocular pain, and eye redness. Ocular pain
was presumably related to secondary glaucoma, iridocycli-
tis, or scleral invasion of the tumor. Ocular pain in the
presented case was thought to be associated with second-
ary glaucoma and iridocyclitis. Another study by Shields
et al. [15] reported that visual acuity was 20/40 or better
in 68 % of cases with iris metastasis of systemic cancer
origin, but unfortunately, over 90 % of the patients with
visual acuity less than 20/40 had ipsilateral choroidal me-
tastasis with retinal detachment. The presented patient
underwent orbital MRI to determine if he had ipsilateral
metastasis, but choroidal infiltration was not observed. In
the most recent study by Shields et al. [8], it was reported
that the most common presenting complaint in patients
with iris metastasis (32 %) was ocular pain.
Pseudohypopyon as a clinical feature of metastatic tu-
mors in the iris was observed in only nine cases in a study
[8]; this rare entity was also noted in the presented case.
In that earlier study [8], fine-needle aspiration biopsy was
performed for cytological confirmation. In unavailable
cases for fine needle aspiration biopsy, the appearance of
the mass lesion yields significant importance of under-
standing the metastasis. Metastatic mass lesions generally
appear in a yellow nodular formation with a mean diam-
eter of 5.9 mm. Although there is considerable variability,
an earlier study reported that the characteristic features of
an iris metastasis can be summarized as a solitary, friable,
yellow-white or fleshy mass that frequently releases tumor
cells into the anterior chamber, which can stimulate an in-
flammatory process and lead to secondary glaucoma [15].
The presented patient’s mass lesion in the iris fulfilled
these criteria, and metastatic iris tumor was the definitive
diagnosis. According to Shields et al. (who have +40 years
of experience in ocular oncology and published the two
largest studies [8, 15] on iris metastasis from systemic can-
cers), the best method for diagnosing iris metastasis is ob-
servation of the typical tumor via slit-lamp biomicroscopy
in a patient with a history of malignancy. When the diag-
nosis is uncertain, the best ancillary diagnostic method is
fine needle aspiration biopsy of the suspicious iris mass
[15]. However, we were unable to perform fine needle as-
piration biopsy since the patient passed away. The major
limitation in this case report is that we do not have the
pathological confirmation of the iris metastasis. However,
we would like to impress in this case study that one could
come up with the diagnosis of iris metastasis from gastric
cancer with the appearance of the multiple iris mass le-
sions in a patient with the history of gastric cancer,
showing the specific features of the iris mass lesions as
described before in patients with the history of systemic
cancer [8]. Metastatic iris lesions were reported to
present as isolated lesions, without concurrent choroid
and/or ciliary body involvement in 61 % of cases [8], as
in the presented case.
The treatment method for iris metastasis depends on
a number of factors. If a patient has advanced, wide-
spread systemic metastasis and the affected eye is rela-
tively asymptomatic, no immediate treatment for the
iris metastasis is necessary. Many patients with iris
metastasis benefit from concurrent chemotherapy, in
terms of local tumor control [15]; however, when
chemotherapy does not result in adequate local tumor
control, external beam irradiation is considered [8, 15].
Ocular outcome in patients with iris metastasis was re-
ported to be positive, with tumor control in 95 % of cases
[8]; however, the overall systemic prognosis was generally
poor [8]. Adequate follow-up was reported in 98 of 104
patients; 85 of the patients died within a median period of
10 months after diagnosis of iris metastasis [8], whereas
the presented patient died just 1 month after iris metasta-
sis was diagnosed.
Conclusions
Iris metastasis of a primary tumor originating from the
gastric region is rare. The presented case shows that gastric
adenocarcinoma can cause isolated metastasis in the iris.
The presented case was diagnosed based on clinical history
and ocular examination. Iris metastasis can masquerade as
iridocyclitis with pseudohypopyon or glaucoma. In patients
with a history of gastric cancer that presents with an iris
mass, uveitis, and high IOP, ocular metastasis of gastric
cancer should be considered.
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